Prescription ·Strong evidence ·Reviewed May 2026
Prescription mood stabilizer and anticonvulsant approved for bipolar mania, epilepsy (multiple seizure types), and migraine prophylaxis. Effective for acute mania and mixed episodes. Carries significant risks including hepatotoxicity, teratogenicity (neural tube defects), pancreatitis, and thrombocytopenia. Contraindicated in pregnancy for psychiatric indications due to high teratogenic risk. Requires serum level monitoring (target 50–125 mcg/mL). Dosage must be determined by your prescribing physician.
The bottom line
Evidence rating strong. Most-documented uses: acute mania treatment, seizure control across multiple types, migraine prophylaxis. 10 sources indexed (2020–2025), with 7 interaction records on file.
Core mechanism
Multiple mechanisms: increases GABA levels through inhibition of GABA transaminase and enhanced GABA synthesis; blocks voltage-gated sodium channels, reducing repetitive neuronal firing; modulates T-type calcium channels; and inhibits histone deacetylase (HDAC), which may contribute to neuroprotective and mood-stabilizing effects.
Take with food to reduce GI upset. Delayed-release and extended-release tablets should be swallowed whole. Sprinkle capsules may be opened and sprinkled on soft food.
Nutrients this medication can lower over time, and what to replace.
Valproate increases urinary carnitine loss and forms valproylcarnitine, which can deplete carnitine stores and impair mitochondrial beta-oxidation.
Valproate is associated with lower folate status and altered one-carbon metabolism during chronic therapy.
Chronic valproate use is associated with lower vitamin D status and impaired bone health.
Long-term valproate therapy is associated with lower bone mineral density and poorer calcium balance.
Valproate therapy may lower biotin status in susceptible users.
Valproic acid inhibits the glucuronidation of lamotrigine, approximately doubling lamotrigine levels. This increases the risk of serious skin reactions including Stevens-Johnson syndrome, especially during lamotrigine titration.
Recommendation: When used together, lamotrigine dose must be reduced by 50% and titrated very slowly. Standard lamotrigine titration schedules have specific reduced-dose protocols for valproate co-administration.
Long-term valproic acid use has been associated with lower 25-hydroxyvitamin D and lower bone mineral density, especially in children and patients treated for years. A randomized trial in children on valproate found daily vitamin D supplementation reduced the decline in vitamin D and bone-mineral markers. This is most relevant for chronic therapy, low sun exposure, low dietary intake, or other fracture risks.
Recommendation: Ask about baseline and follow-up 25-hydroxyvitamin D testing if you take valproic acid long term. Use vitamin D3 supplementation when levels are low or when your clinician recommends prevention. Pair supplementation with bone-health monitoring rather than relying on vitamin D alone.
Valproic acid has been linked with lower bone mineral density in people with epilepsy, particularly with longer treatment duration. Adequate calcium intake is part of bone-health prevention for patients on long-term antiseizure therapy, especially when vitamin D status is also being managed. Calcium does not prevent every valproate-related bone effect, but low intake is a modifiable risk factor.
Recommendation: Make sure your daily calcium intake is appropriate if you take valproic acid long term. Ask about vitamin D testing, dietary calcium review, and bone-density screening if you have fracture risks. Avoid excessive calcium supplementation unless prescribed, particularly if you have kidney stones or kidney disease.
Alcohol can add to valproic acid's dizziness, sleepiness, and impaired coordination, and it may increase concern for liver injury. A case-control study of valproic acid-induced liver injury found alcohol consumption was associated with greater risk of serious DILI. The combination is especially risky with liver disease, elevated liver enzymes, pancreatitis history, high valproate levels, or heavy drinking.
Recommendation: Avoid heavy or binge alcohol while taking valproic acid, and avoid alcohol completely if you have liver disease or abnormal liver tests. Do not skip or double valproic acid doses around drinking without prescriber guidance. Ask about liver-function monitoring and seek urgent care for severe abdominal pain, jaundice, confusion, vomiting, or extreme sleepiness.
L-carnitine is used clinically to address valproic acid-associated carnitine depletion, hyperammonemia, and toxicity risk. Valproic acid can shift mitochondrial metabolism toward toxic metabolites and impair ammonia handling, causing confusion, vomiting, lethargy, or encephalopathy in susceptible patients. This is most important with high valproate levels, overdose, liver disease, young age, poor nutrition, urea-cycle disorders, or unexplained mental-status changes.
Recommendation: Do not self-treat suspected valproic acid toxicity with over-the-counter L-carnitine alone. Seek urgent medical care for confusion, severe sleepiness, repeated vomiting, or sudden neurologic changes while on valproic acid. If your prescriber recommends L-carnitine, use the exact dose and continue ammonia, liver-function, valproate-level, and symptom monitoring as directed.
Vitamin B9, usually as folic acid, has human evidence as an adjunct to sodium valproate in acute mania and is also clinically relevant because valproate is a high-risk teratogen. Folic acid does not make valproic acid safe in pregnancy, but adequate folate status remains important for people who could become pregnant and for one-carbon metabolism. The benefit for mood symptoms is promising but not enough to replace mood stabilizer treatment.
Recommendation: Do not stop or lower valproic acid because you start Vitamin B9. If pregnancy is possible, discuss contraception, pregnancy planning, and folic acid dosing with your prescriber before continuing valproic acid. Use Vitamin B9 as a monitored adjunct, not as protection against valproate's full fetal-risk profile.
Valproic acid has been associated with disturbances in one-carbon metabolism and higher homocysteine in epilepsy studies. Methylfolate may help support folate-dependent methylation when folate status is low or homocysteine is elevated, but it does not make valproic acid safe in pregnancy and should not be presented as protection from valproate teratogenicity. This is most relevant for long-term therapy, pregnancy planning, restricted diets, anemia, neuropathy symptoms, or known folate-pathway variants.
Recommendation: Ask about folate, vitamin B12, and homocysteine testing if you take valproic acid long term or are planning pregnancy. Use methylfolate only as an adjunct and do not change valproic acid dosing without your prescriber. If pregnancy is possible, discuss valproate alternatives and folate strategy before conception because folate does not reliably prevent valproate-associated birth defects.
Numbered references. Citations throughout the page link here.
Camussi D, Marchese M, Nicoletti F et al.. Valproate-Induced Model of Autism in Adult Zebrafish: A Systematic Review. Cells. 2025
Tan S, Ng JS, Tang C et al.. Subcutaneous sodium valproate in palliative care: A systematic review. Palliative medicine. 2024
Valentino K, Teopiz KM, Kwan ATH et al.. Anatomical, behavioral, and cognitive teratogenicity associated with valproic acid: a systematic review. CNS spectrums. 2024
Wong YJ, Fan J, Wan A et al.. Valproic Acid-Associated Hyperammonemia: A Systematic Review. Journal of clinical psychopharmacology. 2023
Liampas I, Siokas V, Brotis A et al.. Intravenous sodium valproate in status epilepticus: review and Meta-analysis. The International journal of neuroscience. 2021
Chaliha D, Albrecht M, Vaccarezza M et al.. A Systematic Review of the Valproic-Acid-Induced Rodent Model of Autism. Developmental neuroscience. 2020
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
NutriStack